IDH1 and neoplasm: More precisely, targeting a single mutation (as tyrosine kinase inhibitors for BCR::ABL1 fusion gene, FLT3 or IDH1/2 mutations) is not the “magic bullet” since leukemia heterogeneity will allow tumor escape via clonal drift under chemotherapy pressure.